Cerebral amyloid angiopathy (CAA), due to vascular amyloid β (Aβ) deposition, is a risk factor for intracerebral hemorrhage and dementia. CAA can occur in sporadic or rare hereditary forms, and is almost invariably associated with Alzheimer's disease (AD). Experimental (animal) models are of great interest in studying mechanisms and potential treatments for CAA. Naturally occurring animal models of CAA exist, including cats, dogs and non-human primates, which can be used for longitudinal studies. However, due to ethical considerations and low throughput of these models, other animal models are more favourable for research. In the past two decades, a variety of transgenic mouse models expressing the human Aβ precursor protein (APP) has been developed. Many of these mouse models develop CAA in addition to senile plaques, whereas some of these models were generated specifically to study CAA. In addition, other animal models make use of a second stimulus, such as hypoperfusion or hyperhomocysteinemia, to accelerate CAA. In this manuscript, we provide a comprehensive review of existing animal models for CAA, which can aid in understanding the pathophysiology of CAA and explore the response to potential therapies.
Cerebral amyloid angiopathy (CAA)
Cerebral amyloid angiopathy (CAA) results from accumulation of amyloidogenic proteins in cerebral arteries, arterioles and capillaries ( fig. 1 ). The most prevalent form of CAA involves the accumulation of the amyloid β protein (Aβ) (2, 3) . CAA often occurs sporadically, being observed in 30% of non-demented elderly individuals and in >80% of all patients with Alzheimer's disease (AD) (4, 5) . CAA can also occur as a rare, monogenetic hereditary disorder, that results from mutations within the Aβ sequence of the human Aβ precursor protein (APP) and also mutations in the presenilin-1 and presenilin-2 genes, involved in cleavage of APP to produce Aβ (6, 7) . Hereditary CAA is characterized by an earlier age of onset, a more severe clinical course and reduced life expectancy, compared to sporadic CAA (8) . For example, patients with hereditary cerebral hemorrhage with amyloidosis -Dutch type (HCHWA-D), caused by the E693Q mutation in the APP gene, suffer from hemorrhagic strokes, infarcts and vascular dementia (9) . Life expectancy is severely reduced; the first stroke occurs between the ages of 40 and 65 years and is often fatal. Surviving patients suffer from recurrent strokes (10, 11) . Patients with hereditary CAA present with a relatively pure form of this condition where Aβ deposition is primarily found in the vasculature.
Therefore, animal models expressing APP with similar mutations may serve as suitable CAA models.
Several other mutations in the APP gene have been identified, such as the Swedish and London mutations ( Fig. 1) (8, 12) . Most of these genes are associated with familial AD, but also increase the risk of developing AD-associated CAA. Animal models harbouring such mutations may therefore serve as models for ADrelated CAA.
Morphology and topography of human CAA
Two forms of CAA, based on the location of Aβ deposition, can be distinguished: CAA type 1 and type 2 (13) . In the more common CAA type 2, Aβ is restricted to vessel walls of cortical and meningeal arteries and arterioles ( fig.1 B & C) , without Aβ deposition in capillaries. Because Aβ is confined within the vessel wall in CAA type 2, this type is not typically associated with brain parenchymal neuroinflammation, but, rather, promotes smooth muscle cell death and hemorrhages. By contrast, in CAA type 1, Aβ is also deposited in the cortical capillaries ( fig.1 A) , and may penetrate into the surrounding brain parenchyma ("dyshoric angiopathy" (2, 13)), which induces a neuroinflammatory response. CAA type 1 is associated with the apolipoprotein E (APOE) ε4 allele, which is also a risk factor for AD, whereas CAA type 2 is associated with the APOE ε2 allele (13) .
Aβ deposition often starts in the tunica adventitia and the abluminal part of the tunica media, and surrounds the smooth muscle cells (14) . As the CAA progresses, all layers of the vessel wall become affected and a loss of smooth muscle cells becomes apparent, whereas endothelial cells are usually preserved (2) .
CAA is mainly composed of Aβ40, and contains to a lesser extent the slightly longer Aβ42. This is in contrast to parenchymal plaques, of which Aβ42 is the main constituent (15) (16) (17) . In addition, other Aβ isoforms are observed in CAA, such as C-terminal (15, 18) or N-terminal truncated Aβ isoforms (19) and pyro-glutamate modified Aβ isoforms (20) . The brain region most frequently and severely affected by Aβ deposition is the occipital lobe, followed by frontal, parietal and temporal lobes; the cerebellum may also be involved, but the white matter, basal ganglia and brainstem are only rarely affected (2, 21, 22) .
Leptomeningeal vessels are more frequently affected than cortical vessels. It is thus assumed that leptomeningeal vessels are affected earlier, while cortical vessels become involved in later stages of CAA (2) . Veins are generally less frequently affected than arteries (2, 23).
Aims of this review
Definite CAA can only be diagnosed by post-mortem neuropathological evaluation (24) . A diagnosis of probable CAA during life is established using clinical data, neuroimaging markers including cerebral microbleeds on T2*-weighted magnetic resonance imaging (MRI) and, if available, histopathological findings (24, 25) . However, pre-mortem brain biopsies are rarely available, and current neuroimagingbased diagnostic criteria have high specificity but limited sensitivity. MRI detection in vivo of cortical superficial siderosis (26) or white matter perivascular spaces (27) has promise to increase diagnostic sensitivity. Likewise, functional MRI to detect impaired vascular reactivity due to smooth muscle cell damage can provide information on the downstream functional effects of CAA (28) . Positron emission tomography (PET) imaging with amyloid ligands shows promise but cannot yet reliably discriminate between CAA and cortical amyloid plaques (27, 29) . In addition, longitudinal human CAA research on the disease from early stages is difficult; when CAA is detected through the incidence of cerebral microbleeds or stroke resulting from a large lobar hemorrhage, the disease is already at a late stage.
Because of these limitations of in vivo imaging methods, animal models are needed to better understand the pathophysiology and time course of CAA, to establish new and early diagnostic tools and to trial new potential therapies for efficacy and side effects. This review therefore aims to provide a comprehensive overview of the animal models available for CAA research. We discuss naturally occurring models of CAA, such as non-human primates, cats and dogs. We then consider transgenic mouse models that develop significant CAA, as well as other models that use a trigger to induce CAA in animals. Since CAA based on the deposition of Aβ is the most prevalent form of this condition, this review does not include forms of CAA based on other amyloidogenic proteins (e.g. Cystatin C or A-Bri (30, 31)).
A comprehensive search for original research articles concerning CAA animal models was performed in PubMed and EMBASE. The search consisted of two components, 'cerebral amyloid angiopathy' and 'model', combined with the Syrcle animal filter (32, 33) to restrict the search to animal research (see Table 1 for the complete search strategy). Only studies written in the English language were eligible for inclusion, and reviews, book chapters and conference abstracts were excluded. No date restrictions were applied. Papers were excluded when they did not concern animal research, when they concerned non-CAA related animal models, or when they cited the use of a previously described model without adding new information. The reference lists of the selected articles and relevant reviews were screened for additional potentially relevant articles.
Naturally occurring models

(Non-human) Primates
Compared to human amyloid pathology, Aβ40 seems to be a more prominent component of parenchymal plaques in non-human primates (orangutans, chimpanzees and rhesus monkeys), whereas both Aβ40 and Aβ42 are found in CAA in these animals (34, 35) . In addition to the non-human primate models described below, CAA is also detected in meningeal and cortical capillaries and arterioles of chimpanzees (Pan troglodytes). These Aβ-containing vessels are also immunopositive for apoE (36) . Although one case report does not report any CAA in an aged (44-year-old) gorilla (Gorilla gorilla) (37) , a more recent case report describes the discovery of Aβ in small blood vessels (38) .
Baboon
The presence of CAA has also been reported in aged (26 and 30 years old) baboon monkeys (Papio hamadryas) (39) . In a study that included 6 baboons above the age of 20 years, the cerebrovascular immunoreactivity of Aβ40 and Aβ42 was studied. All animals displayed arteriolar and capillary CAA, with a slightly predominant Aβ42 immunoreactivity (40).
Cynomolgus monkeys
Cynomolgus monkeys (Macaca fascicularis) have both senile plaques and CAA (41, 42) . In a study with 64 cynomolgus monkeys between 2 and 35 years old, CAA was found in 10 out of 16 animals older than 22 years. CAA was observed frequently in capillaries, and in addition, CAA was found in parenchymal arterioles, but less frequently in meningeal arterioles (43) . In animals younger than 21 years, no CAA was seen (43) . A more recent study of cynomolgus monkeys older than 20 years found that, in contrast to human CAA, Aβ appears predominantly in small veins and capillaries (44) . In this study, the frontal and temporal lobes were most commonly affected, followed by the occipital and parietal lobes and the hippocampus (44) . Immunohistochemistry with Aβ40-and Aβ42/43-specific antibodies has revealed that cortical capillaries are predominantly stained by the Aβ42/43-specific antibody, whereas parenchymal and meningeal arterioles are more intensely stained by the Aβ40-specific antibody (45) , which is in concordance with human CAA. CAA-affected cortical blood vessels are also detected by anti-apoE staining, indicating the presence of apoE in these Aβ deposits (41).
Grey mouse lemur
Several studies have reported the presence of CAA in cerebral blood vessels of microcebus monkeys (Microcebus murinus, or grey mouse lemur) (46, 47) . In a study of 8 aged (> 8 years old) microcebus monkeys, all animals had CAA, whereas only 4 had parenchymal plaques. The CAA was found in leptomeningeal and cortical arteries and arterioles, infiltrating the tunica media. In addition, CAA was identified in capillaries (48).
Rhesus monkeys
A study of 81 rhesus monkeys (Macaca mulatta) showed that these animals develop CAA from the age of 20 years, with a prevalence of 8.3% in 20-to 25-year-old monkeys, increasing to 37.5% in 33-to 39-yearold monkeys (49) . CAA is usually less common than the development of amyloid plaques in this species (50) . Large cortical and meningeal arterioles are most commonly affected, with some minor involvement of capillaries and venules. In contrast to humans, CAA is rarely found in the occipital lobe and more abundantly in the frontal and temporal lobes (50) . Aβ-containing vessels are also immunopositive for apoE, indicating the presence of this protein (51).
Squirrel monkeys
In squirrel monkeys (Saimiri sciureus), in contrast to rhesus monkeys, CAA, rather than senile plaques, is the predominant form of Aβ deposition in (50, 52, 53) . In a study of 9 squirrel monkeys ranging from 8 to 27 years of age, all aged (>22 years old) animals had Aβ in association with meningeal and cortical arterioles and capillaries (52) . In contrast to humans, in which the occipital lobe is the brain region most severely and frequently affected, CAA development in squirrel monkeys is greatest in the rostral cortex while the occipital lobe is relatively spared (54) . In addition, unlike human CAA in which larger arteries are most commonly affected, CAA in squirrel monkeys is characterized by abundant Aβ in the capillaries (55) .
Aβ40 is deposited predominantly in the arterioles, whereas Aβ42 is found mainly in cortical capillaries (56) , which is similar to human CAA (57) . Aged squirrel monkeys have decreased Aβ clearance at the BBB, which is thought to cause or contribute to the development of CAA (56).
Vervet monkey
In a study of 3 aged (15, 22 and 30 years) vervet monkeys (Chlorocebus pygerythrus), Aβ was found in leptomeningeal and cortical blood vessels but not in plaques. These vessels were predominantly positive for Aβ40, but also Aβ42 was detected (58) . As in humans, the occipital cortex is most severely affected by Aβ (58) . A case report of a 29-year-old vervet monkey reports the presence of apoE in CAA (59).
Cats
A study from 1995 showed that aged (> 15 years old) cats have extensive Aβ deposits, some of which are vessel-associated. These vascular deposits had weak staining for both Aβ40 and Aβ42 (60) . Another study found Aβ-positive vessels (arterioles and capillaries) only in the oldest (20 years) of 7 studied cats (61).
These vessels were identified with Congo Red staining or an anti-Aβ40 antibody, indicating the presence of Aβ40 in these vessels. However, in another study, immunohistochemistry with Aβ40-and Aβ42-specific antibodies detected only Aβ42-containing vascular deposits, especially in the white matter of the prefrontal cortex (62) . In a study from 2005, Aβ expression in the brain of Siamese and Domestic Shorthair cats (7.5-to 21-years-old) was examined by immunohistochemistry (63) . Coronal brain slices were stained with Congo red or Aβ-specific antibodies. In addition to senile plaques, CAA was detected in meningeal and cerebral vessels and around cerebral capillaries. Siamese cats were more prone to develop CAA than Domestic Shorthair cats. Vascular deposition generally started around 12 years of age and gradually increased with age. Vascular amyloid was more prominently stained by an Aβ42-specific antibody than by an Aβ40 or pan-Aβ antibody, indicating that in contrast to human CAA, Aβ42 is the most prominent constituent of feline CAA (63).
Dogs
CAA in the brains of aged dogs was first observed in 1956 (64) . These results have been confirmed many times in the 1990s, when much attention went towards the characterization of canine CAA (65) (66) (67) (68) (69) (70) . CAA is detected in a broad range of breeds (65, (71) (72) (73) . In an extensive study of 90 dogs aged 0-19 years, CAA was detected in 28 dogs in an age-dependent manner. CAA was first detected in 9-year old dogs with an incidence increasing to 100% in 15-year old dogs, often accompanied by cerebral hemorrhages (67) . With immunohistochemistry and immunoelectron microscopy, it was discovered that amyloid deposits occur in leptomeningeal and cortical arteries and capillaries of most aged dogs (10-22 years) (74) . These results are confirmed by a study of 30 mongrels, of which all animals older than 13.2 years had CAA (75). Thus CAA incidence and severity in dogs appear to increase with age (75, 76) .
Another study of dogs aged 10 to 17 years showed that meningeal vessels of the dorsal cerebrum, and to a lesser degree the cerebellum, are first affected. In advanced stages, penetrating cortical vessels and meningeal arteries of other brain regions (except the ventral area) are affected (77) . In general, the frontal, parietal and entorhinal cortices seem to be most commonly affected (74, 78) . In addition to CAA, senile plaques are also found in the canine cortex (67, 77) . Although parenchymal plaques mainly consist of Aβ42, canine vascular Aβ consists mainly of Aβ40 (72, 79) , which is similar to humans. Also, pyroglutamate modified Aβ isoforms are found in canine CAA (78, 80) . Amyloid accumulation is first found in the tunica media of large vessels, leading to degeneration of smooth muscle cells (71, 74, 75) . As not all Aβ-positive vessels are detected by Thioflavin S, vascular deposits may contain non-fibrillar Aβ (75) . In addition, other constituents such as apoE, cathepsin D, cystatin C and α-1-antichymotrypsin are found (81) .
In summary, several naturally occurring animal models of CAA exist (table 2) . Cats only exhibit limited vascular Aβ compared to parenchymal deposits, which, in combination with the late age of CAA onset, makes them an unfavourable model. Overall, canine CAA seems most comparable to the human form, and the similar exposure to human diet and living environments add to their suitability as a CAA model. However, the late age of onset is again a major draw-back of this model. Non-human primates are also a physiological relevant model for human CAA, because of their close homology to humans and spontaneous occurrence of CAA. However, the late age of CAA onset (table 2), ethical considerations and high costs impede the use of primates for large studies. An exception may be microcebus monkeys; their relatively short live span (< 18 years) and the predominant development of CAA over parenchymal plaques make this animal an attractive model to study CAA (82).
Mouse models
Transgenic mouse models
APPDutch mice
APPDutch mice are generated by overexpression (± 5-fold) of the E693Q-mutated human APP751 under control of the neuron-specific Thy1 promotor element. These mice develop vascular amyloid deposits at approximately 22-25 months of age, first in leptomeningeal vessels, followed by cortical vessels, with an earlier onset for female mice (83) . In contrast to the majority of transgenic CAA mouse models, in which CAA develops secondary to AD-related plaque pathology, APPDutch mice were primarily designed to study CAA. CAA Aβ40 immunoreactivity is stronger compared to Aβ42, and the AβD40:AβD42 ratio is 4 times higher compared to the Aβ40:Aβ42 ratio in APPwt mice (expressing human wild-type APP under control of the same promotor) (83) . Vascular deposition of AβD40 is accompanied by irregular thickening of the basement membrane and deposition of amyloid fibrils in the basement membrane (predominantly at the adventitial side), which results in severe loss of smooth muscle cells while the endothelial cell layer remains intact.
Hemorrhages occur in aged mice (29 months old) (83) . No dense plaques are found and diffuse parenchymal plaques are rarely detected, whereas in APPwt mice, amyloid is mainly targeted towards the parenchyma. This indicates that the E693Q amino acid substitution is sufficient to target Aβ towards the vessel walls. In the close vicinity of amyloid-laden vessels, perivascular microglial reactions are detected, and astrocytes are activated in affected neocortical areas (83) .
Mice overexpressing human BACE1 (Beta-secretase 1, an enzyme involved in Aβ production) produce excessive amounts of Aβ by increased cleaving at the β-site of APP (84) . Crossbreeding of APPDutch mice with BACE1 transgenic mice leads to a moderately accelerated formation of CAA compared to the APPDutch mice, i.e. they develop CAA at 22 months of age, mainly in the thalamus. In addition, some parenchymal deposition of Aβ in cortex and subiculum is observed. Like in APPDutch mice, the predominant Aβ species in APPDutch/BACE1 double transgenic mice is AβD40 (85) .
Taken together, the development of CAA in the absence of parenchymal plaques makes APPDutch mice an attractive model of hereditary human CAA, but a significant drawback of this model is the late age of onset.
Tg-SwDI
Another transgenic mouse model that was primarily designed to study CAA, is the Tg-SwDI mouse model. These mice express human APP770 containing the Swedish, Dutch and Iowa (D694N) mutations under control of the mouse Thy1 promoter, with expression levels lower (<50%) than those of endogenous mouse APP (86) . In the cortex, Aβ is primarily deposited as plaques, although they are mainly of diffuse form and not stained by Thioflavin S (86, 87) . Notably, microvascular Aβ deposition is observed, predominantly in the thalamus and subiculum (86, 87) . Already at 3 months of age, amyloid levels in the thalamic and subicular microvasculature are higher compared with the rest of the forebrain (86) . CAA is first observed at 3 months of age (86, 87) and at 12 months of age, Aβ40 and Aβ42 levels in thalamic/subicular brain microvessels are 12-and 14-fold higher than those in whole forebrain tissue homogenates (86) . At 12 months of age, 50% of the microvasculature is affected (86), increasing to 85-90% at the age of 24 months (87) . In contrast to the subiculum and thalamus, the vessels in the frontotemporal cortex are only minimally affected by CAA (87) . Although some arterioles are affected, the amyloid pathology is most prominent in the capillaries, which is less frequently observed in sporadic human CAA. Microhemorrhages are seen incidentally, but they are not a prominent feature of Tg-SwDI mice (86) . With ELISA, higher levels of Aβ40 compared to Aβ42 have been measured in isolated cerebral microvessels (87) .
At 3 months of age, Tg-SwDI mice exhibit impaired spatial learning and memory, which coincides with the development of subicular microvascular amyloid and increased numbers of reactive astrocytes and activated microglia (88) .
The accumulation of Aβ in vessels is accompanied by a loss of smooth muscle cells and apoptosis of vascular cells (87) . Microvessel densities are reduced as a result of CAA in the subicular and thalamic regions (87) . Laser-Doppler flowmetry in Tg-SwDI mice showed that these mice have reduced cerebral blood flow responses to different stimulants when compared with wild-type mice (89) .
In a study comparing Tg-SwDI to Tg-Sw mice (the same mice, but lacking the Dutch and Iowa mutations), Aβ was measured in plasma over time. In Tg-Sw mice, that do not develop Aβ deposits in the parenchyma or vasculature up to 2 years of age, stable amounts of Aβ were measured from 3 to 24 months of age. In contrast, no Aβ was measured in plasma of Tg-SwDI mice at any time point up to 2 years of age.
These findings indicate that Tg-SwDI mice have diminished clearance of Aβ across the vasculature into the circulation (90) . These results are supported by increased brain retention times of intracerebrally injected Dutch/Iowa mutant Aβ, compared to injected wild-type Aβ (86) .
Tg-SwDI mice have increased numbers of reactive astrocytes and activated microglia associated with amyloid-laden microvessels (87) , with numbers being the highest in the thalamus and subiculum. In addition, levels of the inflammatory cytokines IL-6 and IL-1β are elevated in Tg-SwDI mice. These findings indicate that CAA in the microvasculature is associated with neuroinflammation (87) . Furthermore, the complement components C1q, C3 and C4 are strongly expressed in the microvasculature of the thalamus, hippocampus and subiculum of Tg-SwDI mice (91) .
ApoE is strongly associated with amyloid deposits in the microvasculature (92) . Tg-SwDI mice bred onto a human APOE ε2/ε2, ε3/ε3 or ε4/ε4 background display a shift of fibrillar amyloid from the microvasculature to the parenchyma (93, 94) . When Tg-SwDI mice are bred onto an apoE knock-out background, fibrillar cerebral microvascular Aβ deposition is reduced (95) . Interestingly, this is not due to changed levels of total Aβ or increased levels of soluble Aβ. Tg-SwDI/apoE +/+ mice have increased numbers of reactive astrocytes and activated microglia and elevated IL-6 levels compared to Tg-SwDI/apoE -/-mice (95) . Similarly, blocking the Aβ-apoE interaction results in a reduction of amyloid burden, microhemorrhages, inflammation, and a reduction of cognitive impairments (96) .
Cholinergic pathways seem to be involved in AD pathology (97) . For instance, alterations of the muscarinic receptor 1 (M1R) influence AD pathology, and M1R agonists have been proposed as AD therapy (98) . Crossbreeding Tg-SwDI with M1R -/-mice leads to an extensive acceleration of vascular Aβ deposition, presumably by altering APP processing in favour of the amyloidogenic pathway (99) .
In summary, Tg-SwDI mice develop early-onset CAA, predominantly in capillaries, whereas larger vessels are relatively spared. Parenchymal deposits occur, but they are not of fibrillar nature. This model exhibits CAA-associated cognitive impairment and displays a robust neuroinflammatory response. Taken together, Tg-SwDI mice provide a unique and valuable model to study CAA type 1.
APP/London mice
APP/London (APP/Ld) mice overexpress (2-to 3-fold) the London mutant (V717I) of the human APP695
gene, under control of the neuron specific mouse Thy-1 gene promoter (100) . Histological analysis has revealed that, in addition to plaques, APP/Ld mice develop substantial CAA after 15 to 24 months (10-50 affected vessels per coronal brain section) (101), first in leptomeningeal vessels, later followed by cortical, thalamic and hippocampal vessels (101) . CAA deposition increases with age, and vascular accumulation occurs somewhat later than the first plaque appearances. Arteries are more frequently affected than veins.
Although capillaries are only rarely affected, some capillaries have CAA deposits with amyloid extending into the neuropil (101).
In concordance with human CAA, there is a pattern of concentric ring accumulations in severely affected vessels, whereas less affected vessels show focal accumulations (101) . Amyloid in the leptomeningeal arterioles accounts for 70% of total vascular amyloid load, versus 30% in cortical vessels (101) . In 20-to 24-month-old mice, neither hemorrhages nor alterations in cerebral blood flow are detected, despite the presence of aneurysms (101, 102) . Electron microscopy shows that, similar to human CAA, amyloid deposition starts in the abluminal part of the tunica media and spreads towards the internal elastic lamina, interrupting the smooth muscle layer. In addition, Aβ40 levels are significantly higher in leptomeningeal blood vessels compared to plaques (101) .
APP/LdxPS1/Mut mice have an additional incorporation of the PS1-A246E mutation (that selectively increases levels of Aβ42), which results in a significant increase in both plaque and vascular amyloid severity, and the development of plaques and CAA already at the age of 6-9 months (103). 
APP23
APP23 mice overexpress (7-fold) human APP751 with the Swedish double mutation (K670N/M671L) under control of the neuron-specific mouse Thy-1 gene promoter (104) (105) (106) . In addition to plaques, which start to deposit at 6 months of age, these mice develop CAA in leptomeningeal, cortical and hippocampal vessels in an age-dependent matter, with an onset around 9 to 12 months of age (104, 106, 107) . Thalamic vessels are affected as well (104, 108) . The thalamus is an important site of CAA in APP23 mice, in contrast to human CAA (108, 109) . CAA formation occurs predominantly in arterioles and capillaries (104) .
Immunohistochemistry and electron microscopy have shown that in some cortical and thalamic vessels (mostly capillaries), amyloid penetrates into the neuropil, resulting in the activation of microglia (104) .
Similar to human CAA, arteries are more frequently affected than veins, and amyloid fibrils are most commonly found in association with the abluminal side of the vessel wall (104).
When total vascular amyloid load in isolated vascular trees of 22-month-old APP23 mice is analyzed with Thioflavin S staining, a very heavy amyloid load in arteries and arterioles of APP23 mice is seen, compared to a relatively moderate amyloid load in Tg2576 mice, a commonly used AD mouse model (107) . Immunostaining with Aβ40-and Aβ42-specific antibodies has revealed a predominance of Aβ40 (108) .
Confocal microscopy with double-labelling for Aβ and smooth muscle cell actin has shown loss of smooth muscle cells in the tunica media of CAA-affected vessels in 19-and 27-month old mice. As a consequence, vessels walls are weakening, leading to aneurysm-like vasodilatation (108), which results in cerebral microhemorrhages in older APP23 animals (104, 108) . The first microhemorrhages occur at 16 months of age, with numbers increasing with age (110, 111) . Two-thirds of the bleeds are detected in the cortex and one third in the thalamus (110) . The latter is in contrast to human CAA in which bleeds are predominantly cortical.
CAA in APP23 mice is directly related to alterations in cerebral circulation. CAA causes microvascular alterations that can be detected by magnetic resonance angiography (MRA) or MRI (109, 112, 113) . In 25-month-old mice, but not in 7.5-month old mice, hemodynamic responses to GABAA are compromised (114) . Cerebral blood flow is decreased in 16-month-old APP23 mice, and continues to decrease with age. This loss of perfusion is correlated to amyloid-burden detected by PET-MRI with
[11C]Pittsburgh compound B (111).
APP23 mice develop significant age-related CAA with an onset at 9-12 months, in association with neuroinflammation and hemorrhages. A difference to human CAA is the strong involvement of the thalamus. As in APP23 mice capillaries are frequently affected by CAA, these mice may serve as a suitable model for CAA type 1.
ArcAβ mice
ArcAβ mice overexpress (6-fold) human APP695 containing the Arctic (E693G) and Swedish mutations under control of the prion protein (PrP) promotor (115) . In these mice, Aβ40 is the predominant peptide, but also Aβ38 and Aβ42 are found (115) . Between 9 and 15 months of age, ArcAβ mice develop dense-core plaques and CAA in an age-dependent manner, in addition to intracellular Aβ deposits (115) . As a result, vascular reactivity in response to a vasodilatory stimulus is decreased (116) . In old mice (16-to 22-months-old), the smooth muscle layer of amyloid-affected vessels is disrupted (117) . Cerebral microbleeds are found in 18-month old ArcAβ mice, in contrast to wild-type controls (118) .
Similar to humans, in ArcAβ mice CAA is predominantly found in smaller vessels (119) , mostly in cortical areas while the thalamus is almost completely spared (119). ArcAβ mice display age-dependent changes of the cerebral vasculature, such as a reduction of functional intracortical microvessel density, whereas larger vessels are spared (119) . Already at 6 months of age, astrogliosis is observed around blood vessels, with severity increasing with age (117) . Connections between astrocytic endfeet and vessel walls are disrupted, leading to disturbed neurovascular coupling. At 9 to 13 months of age, ArcAβ mice have decreased expression of the glucose transporter GLUT1 at the BBB, which results in impaired blood-tobrain glucose transport (117).
The ArcAβ model has mainly been characterized by means of neuroimaging methods. However, severe CAA development, accompanied by neuroinflammation, hemorrhages and reduced cerebrovascular functioning, indicate the suitability of ArcAβ mice as CAA model.
PDAPP mice
PDAPP mice overexpress (18-fold) human APP770 with the V717F Indiana mutation under control of the platelet-derived growth factor (PDGF)-β (120). Aβ deposition in vessels starts around 7 to 10 months of age, and increases with age, but to a substantially lesser degree compared to Tg2576 mice (121, 122) .
PDAPP mice develop microhemorrhages in association with CAA (121). In vivo multi-photon imaging after
Thioflavin S injection shows that 15-to 21-month-old PDAPP mice develop CAA especially in the proximity of vessel branches (123) . The leptomeninges seem to be the predominant site for vascular Aβ deposition in PDAPP mice (124, 125) . Like in other transgenic mice models for CAA, the Aβ40:Aβ42 ratio in PDAPP mice is increased in the cerebral vasculature compared to the whole brain (121, 125) .
Although many reports only mention minimal CAA development in PDAPP mice, several studies have used the PDAPP model to study CAA. Because of the similarity of CAA and plaque distribution and morphology compared to AD patients, this model might be of interest to study AD-related CAA.
Tg2576 mice
Tg2576 mice (synonym APPSwe) overexpress (± 5.5-fold) the human APP695 gene with the Swedish double mutation, under control of the hamster PrP promoter (126) . This model is one of the most widely studied transgenic mouse models for AD. In addition to parenchymal Aβ deposition, vascular Aβ deposition starts to develop at 7 to 10 months of age (121, 122, 127) , in both leptomeningeal and cortical blood vessels Multiphoton imaging can also be used to study the architecture of SMCs in Tg2576 mice. While at 6 months of age SMCs look normal, in 14-and 24-month-old transgenic mice, Thioflavin S positive vessels are accompanied by a disrupted SMC layer. In 24-month-old mice, SMCs are lost in areas of severe amyloid deposition (131) . These effects of amyloid deposition on SMC architecture have been confirmed later by a similar study (133) . As a result of impaired SMC architecture, Tg2576 mice with CAA have a dose-and age-dependent impairment of vasomotor function (131, 133, 134) . Interestingly, already in 6-month-old mice, that not yet have CAA deposition, vasomotor function is decreased, most likely due to elevated soluble Aβ levels (133) . MRA provides an alternative tool to detect blood flow alterations in Tg2576 mice.
MRA of 18-month-old Tg2576 mice followed by histological analysis of amyloid in the brain indicates that CAA may indeed have a causal role on blood flow alterations (135) . Assessing the cerebrovascular distribution of dextran after injection into the hippocampus provides insight into perivascular drainage efficacy. Compared to wild-type mice, Tg2576 mice have disrupted perivascular drainage of dextran (127) .
Tg2576/apoE -/-mice however, have no CAA deposits, indicating that apoE influences vascular deposition of Aβ in this model (121, 128) . In addition, these Tg2576/apoE -/-mice have a substantially reduced number of microhemorrhages (121) . When the human APOE ε4 gene is knocked-in in Tg2576 mice, onset of CAA development is delayed. However, these mice display a shift in Aβ deposition; Aβ is found almost exclusively in the vasculature with only very few plaques. This might be due to the elevated Aβ40:Aβ42 ratio caused by APOE ε4 knock-in (136).
S100B is a proinflammatory molecule, and when this molecule is overexpressed in Tg2576 mice, both parenchymal plaque and CAA development are increased. In addition, neuroinflammation is increased, as microgliosis and astrocytosis are augmented and levels of cytokines are elevated (137) .
In summary, Tg2576 mice develop CAA and plaques. However, CAA is a less prominent feature in Tg2576 compared to APP23 mice and might therefore be less favourable as model for sporadic CAA. It might be better suited as research model for AD with associated CAA pathology.
TgCRND8
TgCRND8 mice express the Swedish double mutation and the Indiana mutation of human APP695 under the control of the Syrian hamster PrP gene promotor, resulting in ± 5-fold higher expression of APP (138) . In addition to diffuse and dense core plaques, that start to develop at 3 months of age, CAA has been detected in these mice by Thioflavin S staining already at 5.5 months of age (138) . Another study has detected Aβ-positive blood vessels already at 4 months of age (139) . Multiphoton microscopy of intact brains, after staining with Thioflavin S, shows that TgCRND8 mice have severe Aβ deposition in leptomeningeal vessels at 11 months of age (122) . The temporal development of CAA in this model has been evaluated by Thioflavin S staining of tissue sections of early-stage CAA (2-3 months), mid-stage CAA (4-6 months) and late-stage CAA (7-12 months) mice. Already at 4 months of age, numerous amyloidpositive blood vessels are detected, and the extent of vascular deposition increases with age (140) . The pattern of leptomeningeal and cortical vascular Aβ deposition is similar to human CAA (139, 141) . In TgCRND8 mice, CAA affects microvessels and arterioles (142), but not venules (140) . Analysis of Aβ isoform distribution by ELISA has revealed that Aβ42 levels in CAA are comparable to the amounts in the cortex, whereas there is significantly more Aβ40 in vessels relative to cortex (140) , which is in concordance with human CAA. Aβ deposition is accompanied by an in increase in tortuosity of penetrating arterials and narrowing of the arteriolar lumen, both indications of microvascular impairment (140) . Interestingly, although Thioflavin S staining detects amyloid deposition in penetration cortical arterioles, and not in penetrating cortical venules, loss of mural cells (pericytes and smooth muscle cells) has only been detected in the latter (143) .
TgCRND8 mice develop CAA already a few months after birth, with a pattern similar to human CAA. However, one should keep in mind that there is extensive plaque development as well, and that the Aβ pathology is therefore of mixed nature.
Other APP transgenic mouse models
In addition to the previously described widely used models for CAA, some models exist that are less known or less well characterized for CAA, but nonetheless develop CAA and should therefore be mentioned.
APP/PS1 mice (APPswe/PSEN1de9, expressing human APP containing the Swedish mutation and presenilin-1 with exon 9 deletion), a well-characterized model for AD with extensive plaque development, also has Aβ accumulation in the vasculature, predominantly in the leptomeninges (144) . CAA development starts around 6 months of age, with an age-dependent increase, but overall CAA development is significantly less pronounced compared to Tg2576 mice (145) . This may be explained by the production of high levels of Aβ42 in this model, whereas levels of the vasculotropic Aβ40 are relatively low (145) . Female APP/PS1 mice develop more severe CAA and subsequent microhemorrhages and neuroinflammation, compared to male mice (146) . Experimental induction of stroke, by occlusion of the middle cerebral artery, seems to increase vascular Aβ burden, as well as plaque development (147) . Another APP/PS model, the APPSweLon/PS1M146L mouse model, starts to develop CAA containing predominantly the Aβ40 isoform, in addition to plaques, already at the age of 18 weeks, with severity increasing with age (148) . A third APP/PS model, APPSwe/ PS1M146V (named ARTE10) also develops CAA as well as plaques (149) .
Although many studies describe only minimal development of CAA in 5xFAD mice (expressing human APP695 with the Swedish, London and Florida (I716V) mutations, as well as the M146L and L286V mutations in human PS1 under control of the mouse Thy1 promoter (150)), some CAA can be detected as early as 3 months of age using multi-photon imaging. CAA is observed in larger cortical and leptomeningeal vessels, with severity increasing with age. Virtually no CAA is detected in the microvasculature (151) . A high-fat diet seems to exacerbate cerebrovascular Aβ pathology (152) .
APP DSL knock-in mice express human APP with the Dutch, Swedish and London mutations.
Crossing these mice with PS1 M146V mice results in offspring that develops robust CAA and parenchymal plaques, starting around 10 to 12 months of age. Around 18 months of age, microhemorrhages occur in these mice, and the introduction of transverse aortic constriction (TAC) exacerbates the development of CAA (153).
E22ΔAβ mice express human APP695 with the Swedish mutation and the Osaka mutation (deletion of amino acid 693). These mice do not develop parenchymal plaques, but show development of vascular amyloid deposits at old age (24 months) in cortical and especially leptomeningeal arteries. Aβ40 is the predominant isoform in these vascular deposits. E22ΔAβ mice display cognitive impairment (154).
Tg-ArcSwe mice express human APP with the Swedish and the Arctic mutations under control of the murine Thy-1 promotor element (155) . These mice develop both parenchymal plaques and CAA (156, 157) . CAA is detected in 8-month-old mice (156) , and at 15 months of age, abundant CAA can be seen in capillaries, arterioles and arteries (157) .
Lastly, BRI-Aβ transgenic mice express Aβ40 of Aβ42 fused with the BRI protein that is involved in British or Danish dementia. BRI-Aβ42 mice develop parenchymal and vascular plaques, whereas BRI-Aβ40 mice do not (158).
Alternative mouse models
Hypoperfusion and hypertension
Hypoperfusion is frequently observed in AD patients and may reinforce Aβ pathology. From that rationale, the induction of hypoperfusion in CAA models may accelerate and exacerbate CAA pathology (159) (160) (161) .
A method frequently used to induce chronic hypoperfusion is bilateral common carotid artery stenosis (BCAS); by causing constriction of these arteries, supply of blood to the brain is reduced. A study that used microcoils to induce BCAS in Tg-SwDI mice shows that as a result, cerebral blood flow is reduced by 26%
and leptomeningeal Aβ accumulation is increased (162) . Another study used ameroid constrictors that gradually narrow the carotid arteries. This may mimic chronic cerebral hypoperfusion more accurately, as perfusion decreased gradually. Using this BCAS technique in APP23 mice results in an increase of CAA in small cortical and leptomeningeal vessels (163) . Another method to induce cerebral hypoperfusion is the constriction of the transverse aorta (TAC), which results in a decrease of cerebral blood flow to the (left side of) the brain. In the APP-DSL model, TAC reduces cerebral blood flow and results in an exacerbation of CAA pathology (153, 164) Another risk factor for the development of vascular dementia is hypertension. Induction of hypertension by administration of angiotensin II results in an exacerbation of CAA in APP-DSL mice (164) .
Similarly, the administration of angiotensin II to APPS1 mice increases cerebral vascular amyloid deposition with 30 to 40% (165) . Nω-Nitro-l-arginine methyl ester hydrochloride (L-NAME) also induces hypertension, and when administrated to Tg-SwDI mice, it accelerates microvascular, but not parenchymal Aβ accumulation with coinciding microglia activation and BBB leakage (166) . Tg2576 mice display increased occurrence of intracerebral hemorrhages after administration of L-NAME (167).
Hyperhomocysteinemia
Homocysteine is an amino acid that is involved in methylation and transsulfuration.
Hyperhomocysteinemia (HHcy) is a risk factor for cerebrovascular diseases (168) . In mice, HHcy can be induced by a deficiency in the vitamins B6, B12 and folate, while supplementing with methionine. When
HHcy is induced in APP/PS1 mice, after six months a shift of Aβ deposition from the parenchyma to the vasculature is observed (169) . Furthermore, an increase of microhemorrhages is observed in both APP/PS1
and WT mice with induced HHcy (169).
3xTg mice express the Swedish mutant APP, mutant PS1 and mutant tau and develop parenchymal plaques, but not CAA. In these mice, 7 months after induction of HHcy, CAA is observed without the occurrence of microhemorrhages (170) . It is hypothesized that the development of CAA is caused by reduced levels of apoE due to HHcy (170) . HHcy in TgCRND8 mice increases CAA in large vessels and capillaries, both 2 and 5 months after induction, in addition to increases in parenchymal plaque load (171).
NOS2 deficiency
Nitric oxide synthase 2 (NOS2) plays a role in vascular functioning and is involved in Aβ production (172) .
Partial deficiency of endothelial NOS results in an increase of CAA in 18-month-old mice, both in the leptomeninges and the cortex. Mild CAA can already be detected in 8-month-old eNOS +/-mice, whereas eNOS +/+ mice show no evidence of CAA (173) . eNOS +/ -mice also display an increase in SMC degeneration and cerebral microhemorrhages (173) .
Knocking out NOS2 in Tg2576 mice increases CAA levels 2-to 5-fold in 52-week-old mice (174) .
Interestingly, no differences in CAA are observed when comparing Tg-SwDI/NOS2 -/-with Tg-SwDI mice (174) . However, Tg-SwDI/NOS2 -/-have a more severe capillary CAA-pathology, including perivascular activated microglia and perivascular phosphorylated-tau, and highly resemble human CAA type 1 (175) .
Hypoperfusion, hypertension, hyperhomocysteinemia and NOS deficiency all play a role in vascular dysfunction, and exacerbate the development of CAA. Hypoperfusion and hyperhomocysteinemia seem to shift Aβ deposition from the parenchyma towards the vasculature. The above-mentioned models may be useful tools in increasing the suitability of models that normally develop only moderate levels of vascular Aβ, or develop CAA at a late age. However, it is likely that these vascular risk factors have undesirable side effects besides CAA development.
Other models
Rats
Although mice are the predominant species used to study and induce CAA, some literature exists on how CAA might be induced in rats to obtain useful CAA models. Treatment with streptozotocin (STZ) can cause insulin resistance, which, given the role of insulin in AD, is hypothesized to lead to Aβ pathology. Rats indeed start to develop CAA three months after STZ treatment (176) . Follow-up research shows an agedependent increase of CAA 6 and 9 months after STZ treatment. CAA is found in cortical and meningeal arteries and arterioles, and is especially pronounced in the thalamus, hypothalamus and hippocampus (177) . This is deviant from human CAA, in which vascular Aβ deposits are only sparsely found in these brain regions.
Another rat model is the F344-AD model that overexpresses two human genes: APP with the Swedish mutation and exon 9 mutant human presenilin-1 (PS1ΔE9). These rats develop both plaques and CAA in an age-dependent manner. CAA is detected in the cerebral cortex, but also in the cerebellum and hippocampus, areas that are less frequently affected in human CAA patients (178) .
TgAPP21 rats overexpress human APP with the Swedish double mutation and the Indiana mutation 
Rabbits
Rabbits do not develop Aβ pathology naturally. However, in a study with 6 rabbits, immunization with thyroglobulin resulted in robust vascular Aβ pathology in 3 out of 6 animals. Although parenchymal plaques were occasionally detected, CAA was the predominant form of Aβ deposition. In two rabbits, small hemorrhages were observed (182) .
Cholinergic pathways may play a role in AD pathology, and based on this hypothesis, Aβ pathology was investigated in a rabbit model with cholinergic deafferentation. In these rabbits, Aβ can be found at the basal lamina of the vasculature, both in larger arteries and capillaries (183) . It is hypothesized that the cholinergic deafferentation leads to increased release of Aβ by neurons, and subsequent diffusion to and accumulation at the vasculature (183).
Experimental models to study the mechanisms of CAA formation
The perivascular drainage pathway comprises the removal of solutes with interstitial fluid (ISF) from the parenchyma by intramural perivascular drainage along the basement membranes of capillaries and arteries. Intracerebral injections of soluble tracers into mice brain have shown that ISF solutes enter the perivascular pathway, move along the basement membrane to leptomeningeal arteries and end up in cervical lymph nodes (184, 185) . It is proposed that this drainage is driven by pulsations of the blood vessel walls (186, 187) . In the ageing mouse brain, perivascular drainage is impaired (127) . Also, the presence of CAA impairs perivascular drainage (127) . For reviews, see (185, (187) (188) (189) .
The concept of paravascular fluid circulation was first described in 1985 (190) , and more recently, this process has been renamed as glymphatic flow. The glymphatic system describes the exchange of solutes between cerebrospinal fluid (CSF) and ISF, and elimination via paravenous pathways. One of the first characterizations of the glymphatic system was achieved by two-photon microscopy in mice. Using fluorescent tracers, it was shown that CSF enters the parenchyma via paravascular spaces around penetrating arteries, and that ISF is cleared through paravenous drainage pathways (191) . Labelled Aβ40 injected into the striatum was shown to be cleared along the glymphatic pathway (191) . Aged mice have reduced clearance of Aβ along paravascular pathways compared to young mice (192) . Aquaporin 4 (AQP4)
is a water channel that is expressed at astrocytic endfeet around the brain vasculature. AQP4 knockout mice have a reduced CSF influx to the parenchyma and a reduced clearance of Aβ40, indicating that AQP4
facilitates transport of CSF into the parenchyma (191) . It is believed that the accumulation of Aβ in the vasculature might be caused by impairment of the glymphatic system, and in turn, that accumulation of Aβ might further impair the glymphatic mechanisms (193) . For reviews, see (193, 194) .
Modelling responses to therapy targeting Aβ
The amyloid cascade hypothesis, putting accumulation of Aβ at a key point in the pathophysiology of AD, has led to exploration of Aβ-targeted therapies for the treatment of AD. Clearance of amyloid plaques from the cortex by anti-Aβ immunotherapeutic approaches leads to an apparent increase in severity of CAA in humans (195) . The side effects associated with Aβ immunotherapy which have hampered most clinical trials seem likely to be due largely to these changes in CAA (196, 197) . Because of the limitations in our ability to study these factors directly in human tissue, experimental models are very important in attempting to understand these therapy-related side effects, in addition to the potential to treat CAA itself by such approaches (83, 124, 198) .
Conclusions
Sporadic CAA poses a significant risk for stroke and dementia, yet there is no treatment and it can still be difficult to diagnose in humans in vivo without a sample of brain tissue, particularly in those at the earlier stages of the disease. Animal models are thus critical to the improvement of our understanding of CAA and the development of new diagnostic and therapeutic tools. CAA occurs naturally in a variety of animals, including non-human primates, cats and dogs. In the early years of CAA research, these models significantly contributed to our knowledge of the pathology of CAA. The spontaneous development of CAA makes these models attractive, as they resemble sporadic CAA in elderly humans. However, their longevity and the relatively late age of CAA onset, high costs, limited access and ethical considerations restrict their wider use in CAA research.
More recently, transgenic mouse models have emerged. These models vary in the degree of CAA and the degree of co-occurrence of parenchymal plaques, but provide us with some key understandings of CAA: 1) vascular Aβ is mainly of neuronal origin (since in most animals the expression of the transgene is driven by a neuronal promoter), 2) CAA seems due to impaired clearance of Aβ by perivascular drainage, and 3) the Aβ40:Aβ42 ratio largely determines whether Aβ accumulates in the brain parenchyma or vessel walls. Their short life span, low expense and the possibilities of genetic manipulations contribute to the attractiveness of mice models. However, there are substantial anatomical and physiological differences between mice and humans, including immune responses which seem to play a pivotal role in CAA.
Extrapolation of results from transgenic mice to humans should therefore be done with care.
Animal models often display only certain aspects of CAA pathology; for instance, CAA is present, but in other brain regions or blood vessel types than in humans, or there is strong evidence of CAA, but without the occurrence of cognitive decline or microbleeds. Therefore, there is an urgent need for more complete models of CAA. However, despite their incompleteness, transgenic mice will remain important tools that will help us to further decipher the pathogenesis of CAA and develop effective therapies. In addition to Aβ transgenic mice models, some other animal models of CAA exist, such as NOS2 -/-models, that will further improve our understanding of CAA pathophysiology.
As no single model for CAA is complete or perfectly resembles human CAA, it is necessary to consider the differences between animal models when selecting a model to address a specific research question. For example, for the study of type 1 CAA in a relatively short time frame, the Tg-SwDI mouse model seems to a useful model, whereas to study CAA type 2, the APP/Ld or APPDutch models seem to be suitable (see table 2 ). With this review, we have provided an overview of animal models that are available for CAA research (table. 2), and their resemblances and differences compared to human CAA.
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